Sec Form 4 Filing - Svennilson Peter @ CONSTELLATION PHARMACEUTICALS INC - 2018-07-23

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Svennilson Peter 2. Issuer Name and Ticker or Trading Symbol CONSTELLATION PHARMACEUTICALS INC [ CNST] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200 3. Date of Earliest Transaction (MM/DD/YY) 07/23/2018 (Street) CAMBRIDGE, MA02142 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/23/2018 C 4,666,888 A 4,677,939 I ( 2 ) ( 3 ) By Funds

$ 0 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Preferred Stock ( 1 ) 07/23/2018 C 11,000,000 ( 1 ) ( 1 ) Common Stock 999,180 0 I ( 3 ) ( 4 ) By Funds Series B Preferred Stock ( 1 ) 07/23/2018 C 8,333,333 ( 1 ) ( 1 ) Common Stock 756,955 $ 0 0 I ( 3 ) ( 4 ) By Funds Series D Preferred Stock ( 1 ) 07/23/2018 C 970,159 ( 1 ) ( 1 ) Common Stock 88,124 $ 0 0 I ( 3 ) ( 4 ) By Funds Series E Preferred Stock ( 1 ) 07/23/2018 C 3,555,555 ( 1 ) ( 1 ) Common Stock 415,244 $ 0 0 I ( 3 ) ( 4 ) By Funds Series E-1 Preferred Stock ( 1 ) 07/23/2018 C 6,502,856 ( 1 ) ( 1 ) Common Stock 590,689 $ 0 0 I ( 5 ) ( 6 ) By Funds Series F Preferred Stock ( 1 ) 07/23/2018 C 20,000,000 ( 1 ) ( 1 ) Common Stock 1,816,696 $ 0 0 I ( 7 ) ( 8 ) By Funds

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Svennilson Peter C/O CONSTELLATION PHARMACEUTICALS, INC. 215 FIRST STREET, SUITE 200 CAMBRIDGE, MA02142 X X Signatures /s/ Jennifer J. Carlson, as Attorney-in-Fact 07/23/2018 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. ( 2 )Consists of 2,554,850 shares of common stock held directly by The Column Group, LP, 1,214,742 shares of common stock held directly by Ponoi Capital, LP and 908,347 shares of common stock held directly by Ponoi Capital II, LP. ( 3 )The Column Group GP, LP is the general partner of The Column Group, LP. Ponoi Management, LLC is the general partner of Ponoi Capital, LP. Ponoi II Management, LLC is the general partner of Ponoi Capital II, LP. The managing partners of The Column Group GP, LP are David Goeddel and Peter Svennilson. The managing partners of Ponoi Management, LLC and Ponoi II Management, LLC are David Goeddel, Peter Svennilson, and Tim Kutzkey. The managing partners of The Column Group GP, LP, Ponoi Management, LLC and Ponoi II Management, LLC, including Peter Svennilson, may be deemed to have voting and investment power with respect to such shares. Mr. Svennilson disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein. ( 4 )The securities are held directly by The Column Group, LP. ( 5 )Consists of an aggregate of 3,251,428 shares of Series E-1 Preferred Stock, which were convertible into 295,347 shares of Common Stock, held directly by The Column Group, LP and 3,251,428 shares of Series E-1 Preferred Stock, which were convertible into 295,342 shares of Common Stock, held directly by Ponoi Capital, LP. The securities held by The Column Group, LP are indirectly held by The Column Group GP, LP, the general partner of The Column Group, LP. ( 6 )(Continued from Footnote 5) The managing partners of The Column Group GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group GP, LP may be deemed to have voting and investment power with respect to such shares. The securities held by Ponoi Capital, LP are indirectly held by Ponoi Management, LLC, the general partner of Ponoi Capital, LP. The managing partners of Ponoi Management, LLC are David Goeddel, Peter Svennilson, and Tim Kutzkey. The managing partners of Ponoi Management, LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. ( 7 )Consists of an aggregate of 10,000,000 shares of Series F Preferred Stock, which were convertible into 908,349 shares of Common Stock, held directly by Ponoi Capital, LP and 10,000,000 shares of Series F Preferred Stock, which were convertible into 908,347 shares of Common Stock, held directly by Ponoi Capital II, LP. The securities held by Ponoi Capital, LP are indirectly held by Ponoi Management, LLC, the general partner of Ponoi Capital, LP. ( 8 )(Continued from Footnote 7) The managing partners of Ponoi Management, LLC are David Goeddel, Peter Svennilson, and Tim Kutzkey. The managing partners of Ponoi Management, LLC may be deemed to have voting and investment power with respect to such shares. The securities held by Ponoi Capital II, LP are indirectly held by Ponoi II Management, LLC, the general partner of Ponoi Capital II, LP. The managing partners of Ponoi II Management, LLC are David Goeddel, Peter Svennilson, and Tim Kutzkey. The managing partners of Ponoi II Management, LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.